Clovis' Perfect Story Gets Shredded
By Max Nisen
Nov 16, 2015
The response rate plunged from 67 percent to 28 percent for a smaller dose and 35 percent for a larger one. AstraZeneca's direct competitor Tagrisso, approved just last week, has a confirmed response rate about double that.
In other words, rocilitenib is, as Bloomberg Intelligence analyst Asthika Goonewardene puts it, "toast."
The Fly On the Wall
11/16/15 5:30 P.M. EST
Leerink Raises AstraZeneca Price Target to $75 after FDA requests added data for rociletinib
Says blocking plaque formation shows cognitive improvement